Lymphoma, Hodgkin, Classic disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

CHL MCID: LYM133 MIFTS: 72	Lymphoma, Hodgkin, Classic (CHL) Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lymphoma, Hodgkin, Classic

MalaCards integrated aliases for Lymphoma, Hodgkin, Classic:

IMPROVED

Name: Lymphoma, Hodgkin, Classic ⁵⁷ ⁷³ ³⁶ ³⁸

Hodgkin Lymphoma ⁵⁷ ¹¹ ¹⁹ ⁵⁸ ⁷⁵ ¹² ⁴¹ ¹⁴ ³¹ ³³

Hodgkin Disease ⁵⁷ ¹¹ ¹⁹ ⁷³ ⁵³ ⁷¹ ³³

Classic Hodgkin Lymphoma ⁵⁸ ²⁸ ⁵

Hodgkin's Lymphoma ¹¹ ¹⁹ ¹⁴

Hodgkins Lymphoma ¹¹ ²⁸ ¹⁶

Chl ⁵⁷ ⁷³

Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb ⁷¹

Classical Hodgkin Lymphoma, Type Not Specified ³³

Hodgkin's Disease of Intrapelvic Lymph Nodes ⁷¹

Stage Ii Subdiaphragmatic Hodgkin Lymphoma ¹¹

Stage I Subdiaphragmatic Hodgkin Lymphoma ¹¹

Lymphoma, Hodgkin, Susceptibility to ³⁸

Hodgkin Lymphoma, Susceptibility to ⁵⁷

Malignant Lymphogranulomatosis ³³

Malignant Hodgkin Lymphoma ³³

Malignant Lymphogranuloma ³³

Classic Hodgkin Disease ⁵⁸

Lymphoma, Hodgkin's ¹⁹

Hodgkin's Sarcoma ¹¹

Hodgkin's Disease ⁷⁵

Hl ¹¹

Characteristics:

Inheritance:

Lymphoma, Hodgkin, Classic: Autosomal recessive ⁵⁷

Hodgkin Lymphoma: Multigenic/multifactorial ⁵⁸

Prevelance:

Classic Hodgkin Lymphoma: 1-9/100000 (Europe, France, United States, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-5/10000 (Europe, Europe) ⁵⁸

Hodgkin Lymphoma: 1-9/100000 (Europe, United States) 1-5/10000 (Europe) ⁵⁸

Age Of Onset:

Classic Hodgkin Lymphoma: All ages ⁵⁸

Hodgkin Lymphoma: Adolescent,Adult,Childhood,Elderly,Infancy ⁵⁸

Age Of Death:

Classic Hodgkin Lymphoma: any age ⁵⁸

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Hodgkin lymphoma

Hodgkin lymphoma, unspecified

Lymphocyte depleted classical Hodgkin lymphoma

Lymphocyte-rich classical Hodgkin lymphoma

Mixed cellularity classical Hodgkin lymphoma

Nodular lymphocyte predominant Hodgkin lymphoma

Nodular sclerosis classical Hodgkin lymphoma

Other classical Hodgkin lymphoma

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Hodgkin lymphoma

Classical Hodgkin lymphoma

Classical Hodgkin lymphoma, unspecified

Hodgkin lymphoma, unspecified

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:8567

OMIM® ⁵⁷ 236000

ICD9CM ³⁴ 201

MeSH ⁴³ D006689

NCIt ⁴⁹ C9357

SNOMED-CT ⁶⁸ 118599009

ICD10 ³¹ C81 C81.9

ICD10 via Orphanet ³² C81.0 C81.1 C81.2 more

UMLS via Orphanet ⁷² C0019829

Orphanet ⁵⁸ ORPHA391 ORPHA98293

MedGen ⁴⁰ C0019829

EFO ¹⁶ EFO_0000183

ICD11 ³³ 1528863768 1528863768/unspecified 1616050398 more

UMLS ⁷¹ C0019829 C0153789 C0153790

Sources

Summaries for Lymphoma, Hodgkin, Classic

MedlinePlus: ⁴¹ What is Hodgkin lymphoma? Hodgkin lymphoma, also called Hodgkin disease, is a type of cancer that develops in the lymph system. Your lymph system is part of your immune system. It helps protect your body from infection and disease. The lymph system is made up of tissues and organs that produce, store, and carry white blood cells. It includes your: Bone marrow Lymph nodes Lymphatic vessels Spleen Thymus Tonsils Hodgkin lymphoma is one of the main types of lymphoma. The other is non-Hodgkin lymphoma. Each type starts in different types of white blood cells. What causes Hodgkin lymphoma? The cause of Hodgkin lymphoma is unknown. But there are certain people who are at higher risk of developing it. Who is more likely to develop Hodgkin lymphoma? Certain factors can make you more likely to develop Hodgkin lymphoma: Age. Hodgkin lymphoma is most common in early adulthood (age 20-39 years) and in late adulthood (age 65 years and older). Being male. The risk of adult Hodgkin lymphoma is slightly higher in males than in females. Past Epstein-Barr virus (EBV) infection. Having an infection with EBV as a young child or teenager increases your risk of Hodgkin lymphoma. A family history of Hodgkin lymphoma. Having a parent or sibling with Hodgkin lymphoma increases your risk of developing it. What are the symptoms of Hodgkin lymphoma? The signs and symptoms of Hodgkin lymphoma may include: Painless, swollen lymph nodes in the neck, underarm, or groin Fever for no known reason Drenching night sweats (very heavy sweating during sleep) Weight loss for no known reason in the past 6 months Itchy skin, especially after bathing or drinking alcohol Fatigue How is Hodgkin lymphoma diagnosed? To find out if you have Hodgkin lymphoma, your provider: Will ask about your symptoms and medical history. This will include checking for signs of disease, such as lumps or anything else that seems unusual. May order some lab tests, such as: Complete blood count Blood chemistry studies Lactate dehydrogenase (LDH) test Erythrocyte sedimentation rate (ESR) test Blood tests to rule out other medical conditions May do imaging tests such as a CT and PET (positron emission tomography) scans May do a lymph node biopsy What are the treatments for Hodgkin lymphoma? Treatments for Hodgkin lymphoma include: Chemotherapy Radiation therapy Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells Cancer immunotherapy Hodgkin lymphoma can usually be cured if it is found and treated early. NIH: National Cancer Institute

MalaCards based summary: Lymphoma, Hodgkin, Classic, also known as hodgkin lymphoma, is related to mantle cell lymphoma and primary cutaneous t-cell non-hodgkin lymphoma. An important gene associated with Lymphoma, Hodgkin, Classic is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are miRNAs involved in DNA damage response and ncRNAs involved in STAT3 signaling in hepatocellular carcinoma. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are fatigue and immunodeficiency

UniProtKB/Swiss-Prot: ⁷³ A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

Orphanet ⁵⁸ Classic hodgkin lymphoma: Classical Hodgkin lymphoma (CHL) is a B-cell lymphoma characterized histologically by the presence of large mononuclear Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells.

Hodgkin lymphoma: Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.

OMIM®: ⁵⁷ Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a minority of malignant cells, known as 'Reed-Sternberg' (RS) cells, mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of 2 nuclei (summary by Salipante et al., 2009). (236000) (Updated 24-Oct-2022)

GARD: ¹⁹ Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.

Disease Ontology: ¹¹ A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

Wikipedia: ⁷⁵ Hodgkin lymphoma (HL) is a type of lymphoma, in which cancer originates from a specific type of white... more...

Sources

Related Diseases for Lymphoma, Hodgkin, Classic

Diseases related to Lymphoma, Hodgkin, Classic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2258)

#	Related Disease	Score	Top Affiliating Genes
1	mantle cell lymphoma	33.0	TP53 TNFRSF8 PAX5 MIR155 IRF4 ALK
2	primary cutaneous t-cell non-hodgkin lymphoma	32.9	TNFRSF8 MIR21 MIR155
3	lymphoma, mucosa-associated lymphoid type	32.9	TP53 TNFRSF8 PAX5 MIR155 IRF4
4	plasmablastic lymphoma	32.7	TNFRSF8 PAX5 IRF4
5	mature t-cell and nk-cell lymphoma	32.6	TP53 TNFRSF8 PAX5 MIR21 MIR155 ALK
6	mediastinal gray zone lymphoma	32.5	TNFRSF8 PAX5
7	hodgkin's lymphoma, nodular sclerosis	32.4	TNFRSF8 PAX5 KLHDC8B
8	hodgkin's lymphoma, lymphocytic depletion	32.3	TNFRSF8 PAX5
9	hepatosplenic t-cell lymphoma	32.3	TNFRSF8 ALK
10	gray zone lymphoma	32.3	TNFRSF8 PAX5 IRF4
11	marginal zone b-cell lymphoma	32.0	TP53 TNFRSF8 PAX5 IRF4
12	chronic lymphocytic leukemia/small lymphocytic lymphoma	31.9	TP53 TNFRSF8 PAX5
13	primary mediastinal b-cell lymphoma	31.8	TNFRSF8 MIR155 IRF4
14	peripheral t-cell lymphoma	31.8	TP53 TNFRSF8 PAX5 MIR21 MIR155 ALK
15	peripheral nervous system disease	31.7	TP53 TNFRSF8 MIR30B MIR30A MIR21 MIR140
16	central nervous system lymphoma	31.5	TNFRSF8 PAX5 MIR18A IRF4
17	bone lymphoma	31.5	TNFRSF8 PAX5 IRF4 ALK
18	breast lymphoma	31.5	TNFRSF8 PAX5 IRF4 ALK
19	skin carcinoma	31.4	TP53 MIR30A MIR21 MIR18A MIR140
20	cardiovascular system disease	31.3	MIR30B MIR30A MIR21 MIR155 MIR140
21	respiratory failure	31.2	MIR30B MIR21 MIR155 CSF3
22	dermatomyositis	31.2	MIR30A MIR21 MIR155
23	adult lymphoma	31.2	TNFRSF8 PAX5 IRF4 ALK
24	childhood lymphoma	31.2	TNFRSF8 PAX5 IRF4 ALK
25	testicular lymphoma	31.1	TNFRSF8 IRF4
26	brain cancer	31.1	TP53 MIR30A MIR21 MIR20A MIR155 MIR140
27	lymphatic system disease	31.1	TP53 TNFRSF8 MIR30A MIR21 MIR20A MIR18A
28	sezary's disease	31.1	TP53 TNFRSF8 MIR155 IRF4 ALK
29	skin melanoma	31.0	TP53 MIR21 MIR200A
30	plasma cell neoplasm	31.0	TP53 PVT1 PAX5 MIR155 MIR140
31	multicentric castleman disease	31.0	TNFRSF8 PAX5 IRF4 ALK
32	arteries, anomalies of	31.0	MIR30B MIR30A MIR21 MIR20A MIR18A MIR155
33	polymyositis	31.0	MIR30A MIR21 MIR155
34	esophageal cancer	31.0	TP53 PVT1 MIR30A MIR21 MIR20A MIR200A
35	immune deficiency disease	30.9	TNFRSF8 MIR30A MIR21 MIR20A MIR155 MIR140
36	interstitial lung disease	30.9	MIR30B MIR30A MIR21 MIR155
37	head and neck cancer	30.9	TP53 MIR30A MIR21 MIR20A MIR200A MIR18A
38	body mass index quantitative trait locus 11	30.9	TP53 MIR30A MIR21 MIR20A MIR18A MIR155
39	central nervous system disease	30.9	MIR30B MIR30A MIR21 MIR20A MIR200A MIR18A
40	leukemia, acute myeloid	30.9	TP53 TNFRSF8 PAX5 MIR374A MIR30A MIR21
41	lung cancer susceptibility 3	30.9	TP53 MIR30A MIR21 MIR200A MIR140 ALK
42	plasmacytoma	30.9	PVT1 PAX5 IRF4
43	hepatocellular carcinoma	30.9	TP53 PVT1 MIR374A MIR30A MIR21 MIR20A
44	lung lymphoma	30.8	TNFRSF8 PAX5 IRF4
45	burkitt lymphoma	30.8	TP53 TNFRSF8 PVT1 PAX5 MIR21 MIR155
46	thyroid gland anaplastic carcinoma	30.8	TP53 MIR30A MIR200A MIR18A ALK
47	bone cancer	30.8	TP53 MIR30A MIR21 MIR186 MIR155 MIR140
48	nervous system disease	30.8	TP53 MIR374A MIR30B MIR30A MIR21 MIR20A
49	interstitial lung disease 2	30.8	TP53 MIR30B MIR30A MIR21 MIR140
50	type 2 diabetes mellitus	30.8	TP53 PVT1 MIR30B MIR30A MIR21 MIR20A

Graphical network of the top 20 diseases related to Lymphoma, Hodgkin, Classic:

Sources

Symptoms & Phenotypes for Lymphoma, Hodgkin, Classic

Human phenotypes related to Lymphoma, Hodgkin, Classic:

⁵⁸ ³⁰ (show all 31)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	fatigue ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%) Very frequent (99-80%)	HP:0012378
2	immunodeficiency ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002721
3	cellular immunodeficiency ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0005374
4	lymphoma ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%) Very frequent (99-80%)	HP:0002665
5	lymphadenopathy ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%) Very frequent (99-80%)	HP:0002716
6	hyperhidrosis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%) Frequent (79-30%)	HP:0000975
7	fever ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%) Frequent (79-30%)	HP:0001945
8	anorexia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%) Frequent (79-30%)	HP:0002039
9	cough ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%) Frequent (79-30%)	HP:0012735
10	chest pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%) Frequent (79-30%)	HP:0100749
11	weight loss ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%) Frequent (79-30%)	HP:0001824
12	pruritus ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%) Frequent (79-30%)	HP:0000989
13	poor appetite ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0004396
14	ataxia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%) Occasional (29-5%)	HP:0001251
15	respiratory insufficiency ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002093
16	splenomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%) Occasional (29-5%)	HP:0001744
17	hepatomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%) Occasional (29-5%)	HP:0002240
18	dyspnea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002094
19	hemoptysis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%) Occasional (29-5%)	HP:0002105
20	peripheral neuropathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%) Occasional (29-5%)	HP:0009830
21	migraine ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002076
22	skin rash ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000988
23	headache ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002315
24	bone pain ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%) Occasional (29-5%)	HP:0002653
25	osteolysis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002797
26	bone marrow hypocellularity ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0005528
27	hodgkin lymphoma ³⁰	Very rare (1%)		HP:0012189
28	neoplasm ⁵⁸		Occasional (29-5%) Occasional (29-5%)
29	abnormality of blood and blood-forming tissues ⁵⁸		Occasional (29-5%)
30	polyclonal elevation of igm ³⁰			HP:0003459
31	impaired lymphocyte transformation with phytohemagglutinin ³⁰			HP:0003347

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 24-Oct-2022)

Lab:
polyclonal elevation of igm
impaired lymphocyte transformation with phytohemagglutinin

Heme:
hodgkin disease

Clinical features from OMIM®:

236000 (Updated 24-Oct-2022)

Sources

Drugs & Therapeutics for Lymphoma, Hodgkin, Classic

Drugs for Lymphoma, Hodgkin, Classic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 583)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Entecavir

Approved, Investigational

Phase 4

142217-69-4

153941

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Nitrous oxide

Approved, Vet_approved

Phase 4

10024-97-2

948

Prilocaine

Approved

Phase 4

721-50-6

4906

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Idarubicin

Approved

Phase 4

58957-92-9

42890

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Pirarubicin

Investigational

Phase 4

72496-41-4

4844

Tenofovir

Experimental, Investigational

Phase 4

147127-20-6, 202138-50-9

464205 6398764

Dexchlorpheniramine

Experimental, Investigational

Phase 4

25523-97-1

33036

Reverse Transcriptase Inhibitors

Phase 4

Antifungal Agents

Phase 4

Angiotensin Receptor Antagonists

Phase 4

Angiotensin II Type 1 Receptor Blockers

Phase 4

Giapreza

Phase 4

Anti-Arrhythmia Agents

Phase 4

Lidocaine, Prilocaine Drug Combination

Phase 4

Sodium Channel Blockers

Phase 4

Anesthetics, Inhalation

Phase 4

Anesthetics, General

Phase 4

Diuretics, Potassium Sparing

Phase 4

Antioxidants

Phase 4

Radiation-Protective Agents

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Hematinics

Phase 4

Chrysarobin

Phase 4

Epoetin Alfa

Phase 4

Tioguanine

Approved

Phase 3

154-42-7

2723601

Enalaprilat

Approved

Phase 3

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 3

75847-73-3

40466924 5388962 5362032

Clarithromycin

Approved

Phase 3

81103-11-9

84029

Metronidazole

Approved

Phase 3

443-48-1, 69198-10-3

4173

Amoxicillin

Approved, Vet_approved

Phase 3

26787-78-0

33613

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Etoposide

Approved

Phase 3

33419-42-0

36462

Aldesleukin

Approved

Phase 2, Phase 3

110942-02-4

Dexrazoxane

Approved, Withdrawn

Phase 3

24584-09-6

71384

Erythromycin

Approved, Investigational, Vet_approved

Phase 3

55-31-2, 114-07-8

12560

Pentamidine

Approved, Investigational

Phase 3

100-33-4

4735

Zoledronic acid

Approved

Phase 3

118072-93-8

68740

Mercaptopurine

Approved

Phase 3

50-44-2

667490

Moxifloxacin

Approved, Investigational

Phase 3

186826-86-8, 354812-41-2, 151096-09-2

152946

Calcium carbonate

Approved, Investigational

Phase 3

471-34-1

Oxaliplatin

Approved, Investigational

Phase 3

61825-94-3

43805 11947679 6857599

Decitabine

Approved, Investigational

Phase 2, Phase 3

2353-33-5

451668

Interventional clinical trials:

(show top 50) (show all 2479)

#	Name	Status	NCT ID	Phase	Drugs
1	An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma	Unknown status	NCT01746992	Phase 4	Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2	PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia	Unknown status	NCT02996617	Phase 4	rhG-CSF regimen;Pegylated rhG-CSF regimen
3	Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Unknown status	NCT04134247	Phase 4	PD-1 combined with chemotherapy;chemotherapy
4	Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy	Unknown status	NCT00188149	Phase 4	Combined chemotherapy (ABVD, BACOPP-D)
5	Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma	Unknown status	NCT02526823	Phase 4	R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
6	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults	Unknown status	NCT00797810	Phase 4	Rituximab
7	A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy	Unknown status	NCT02585947	Phase 4	Tenofovir
8	Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma	Completed	NCT01124526	Phase 4	Rituximab Fludarabine Cyclophosphamide
9	A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy	Completed	NCT01990534	Phase 4	Brentuximab Vedotin
10	Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL)	Completed	NCT02782845	Phase 4	Chemotherapy;Immunochemotherapy;Pegfilgrastim
11	Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture	Completed	NCT00808171	Phase 4	Livopan;EMLA
12	A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg	Completed	NCT01164475	Phase 4	Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
13	An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation	Completed	NCT00352703	Phase 4	Kepivance (Palifermin)
14	Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma	Completed	NCT00168727	Phase 4	ibritumomab tiuxetan (Zevalin®)
15	Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients	Completed	NCT00969462	Phase 4	Doxorubicin
16	Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7)	Completed	NCT00199082	Phase 4	Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
17	The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP	Completed	NCT00162955	Phase 4	Valsartan
18	A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.	Completed	NCT00430352	Phase 4	rituximab [MabThera/Rituxan]
19	Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial	Completed	NCT00926757	Phase 4	Entecavir prophylaxis;Therapeutic entecavir
20	A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA	Completed	NCT01180049	Phase 4	temsirolimus
21	A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens	Completed	NCT00090038	Phase 4	rituximab
22	A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer	Completed	NCT00277160	Phase 4	Neulasta (pegfilgrastim)
23	A Prospective Multi-center Study for the Treatment of Chinese Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Using a Modified COG Strategy	Recruiting	NCT04726501	Phase 4
24	Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.	Recruiting	NCT03500133	Phase 4	Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
25	Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma	Recruiting	NCT05490953	Phase 4	Pentoxifylline;Placebo
26	B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021)	Recruiting	NCT05518383	Phase 4	Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
27	Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study - Intervention Pilot Study	Recruiting	NCT05191225	Phase 4	RiTUXimab Injection [Truxima]
28	First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents	Active, not recruiting	NCT01088750	Phase 4	cyclophosphamide;prednisolone;vinblastine sulfate
29	Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment	Terminated	NCT02608060	Phase 4	Epoetin Beta
30	Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial	Unknown status	NCT01516580	Phase 3	Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
31	The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood	Unknown status	NCT00003728	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
32	Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients	Unknown status	NCT01277172	Phase 2, Phase 3
33	A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma	Unknown status	NCT01570049	Phase 3	Bendamustine
34	Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: a Phase 3 Randomised, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced CardioToxicity	Unknown status	NCT03265574	Phase 3	Enalapril
35	Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma	Unknown status	NCT00816959	Phase 3	R-mabHDI and ABVD;ABVD
36	Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy	Unknown status	NCT00002987	Phase 3	cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
37	A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease)	Unknown status	NCT00003924	Phase 3
38	Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.	Unknown status	NCT02722733	Phase 3	G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
39	Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study)	Unknown status	NCT00154440	Phase 3	proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
40	A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma	Unknown status	NCT00078598	Phase 3	Rituximab or Iodine I 131 Tositumomab Therapy
41	A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab)	Unknown status	NCT00022685	Phase 3
42	A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma	Unknown status	NCT00028717	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
43	Non-Hodgkin's Lymphoma T Cell Protocol	Unknown status	NCT00003423	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
44	A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma	Unknown status	NCT00017290	Phase 3	cyclophosphamide;prednisone;vincristine sulfate
45	Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction	Unknown status	NCT00003639	Phase 3	chlorambucil;dexamethasone;idarubicin
46	A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia	Unknown status	NCT02186574	Phase 3	Tenofovir disoproxil;Placebo Oral Tablet
47	A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups	Unknown status	NCT00003815	Phase 3	carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
48	The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00003338	Phase 2, Phase 3
49	The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00003337	Phase 3
50	Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies	Unknown status	NCT03623087	Phase 3	Cisplatin;Gemcitabine;Etoposide (VP-16);Dexamethasone;L-asparaginase

Search NIH Clinical Center for Lymphoma, Hodgkin, Classic

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Carmustine

Chlorambucil

Cisplatin

CISPLATIN PWDR

Cyclophosphamide

Dacarbazine

Ifosfamide

Lomustine

Mechlorethamine

Mechlorethamine hydrochloride

pembrolizumab

Procarbazine

Procarbazine Hydrochloride

sargramostim

Vinblastine

Vinblastine Sulfate

Vincristine

Vincristine Sulfate

vinorelbine

Vinorelbine tartrate

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Lymphoma, Hodgkin, Classic cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Lymphoma, Hodgkin, Classic:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
	Peripheral blood stem cells for treatment of hematologic malignancies
	StemEx, umbilical cord blood stem/progenitor cells for hematological diseases

Embryonic/Adult Cultured Cells Related to Lymphoma, Hodgkin, Classic:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells
	Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Sources

Genetic Tests for Lymphoma, Hodgkin, Classic

Genetic tests related to Lymphoma, Hodgkin, Classic:

#	Genetic test	Affiliating Genes
1	Classic Hodgkin Lymphoma ²⁸	KLHDC8B
2	Hodgkins Lymphoma ²⁸

Sources

Anatomical Context for Lymphoma, Hodgkin, Classic

Organs/tissues related to Lymphoma, Hodgkin, Classic:

MalaCards : Bone Marrow, Lymph Node, T Cells, Bone, Thymus, Spleen, B Cells

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Hodgkin, Classic:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate
2	Blood Peripheral Blood Mature B-Cells	Affected by disease

Sources

Publications for Lymphoma, Hodgkin, Classic

Articles related to Lymphoma, Hodgkin, Classic:

(show top 50) (show all 59751)

#	Title	Authors	PMID	Year
1	Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. ⁶² ⁵⁷ ⁵	Salipante SJ...Horwitz MS	19706467	2009
2	Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. ⁵³ ⁶² ⁵⁷	Lamprecht B...Mathas S	20436485	2010
3	High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. ⁵³ ⁶² ⁵⁷	Tecchio C...Cassatella MA	17539776	2007
4	Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. ⁵³ ⁶² ⁵⁷	Martin-Subero JI...Siebert R	11830502	2002
5	MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. ⁶² ⁵⁷	Steidl C...Gascoyne RD	21368758	2011
6	A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. ⁶² ⁵⁷	Goldin LR...Tucker MA	15994882	2005
7	Characteristics of Hodgkin's lymphoma after infectious mononucleosis. ⁶² ⁵⁷	Hjalgrim H...Melbye M	14523140	2003
8	Combined segregation and linkage analysis of 59 Hodgkin's disease families indicates the role of HLA determinants. ⁶² ⁵⁷	Shugart YY...Collins A	10878668	2000
9	A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. ⁶² ⁵⁷	Shugart YY...Dong C	10914686	2000
10	Familial Hodgkin's disease: a disease of young adulthood? ⁶² ⁵⁷	Ferraris AM...Boffetta P	9111426	1997
11	Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. ⁶² ⁵⁷	Mack TM...Rappaport EB	7824015	1995
12	Localization of predisposition to Hodgkin disease in the HLA class II region. ⁶² ⁵⁷	Klitz W...Begovich AB	8116619	1994
13	Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. ⁶² ⁵⁷	Deacon EM...Young LS	8381153	1993
14	Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. ⁶² ⁵⁷	Pallesen G...Young LS	1671232	1991
15	Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. ⁶² ⁵⁷	Wu TC...Ambinder RF	2172169	1990
16	Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. ⁶² ⁵⁷	Mueller N...Vogelman J	2537928	1989
17	Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. ⁶² ⁵⁷	Weiss LM...Sklar J	2536894	1989
18	Epstein-Barr viral DNA in tissues of Hodgkin's disease. ⁶² ⁵⁷	Weiss LM...Sklar J	2821817	1987
19	HLA in familial Hodgkin's disease. ⁶² ⁵⁷	Conte R...Zucchelli P	6875280	1983
20	Simultaneous Hodgkin's disease in three siblings with identical HLA-genotype. ⁶² ⁵⁷	Torres A...Nunez-Roldan A	7397649	1980
21	Infectious mononucleosis and Hodgkin's disease. ⁶² ⁵⁷	Munoz N...De-The G	681023	1978
22	Serum genetic markers in a Newfoundland isolate with a familial aggregate of Hodgkin's disease. ⁶² ⁵⁷	Carter ND...West CM	680699	1978
23	HLA in familial Hodgkin's disease. Results and a new hypothesis;. ⁶² ⁵⁷	Marshall WH...Larsen B	844915	1977
24	Hodgkin's disease in siblings. ⁶² ⁵⁷	Grufferman S...Lukes RJ	831107	1977
25	Familial Hodgkin's disease and the major histocompatibility complex. ⁶² ⁵⁷	Bowers TK...Yunis EJ	144365	1977
26	Familial Hodgkin's disease and associated cancer. A clinical-pathologic study. ⁶² ⁵⁷	Lynch HT...Thomas R	991117	1976
27	Varied manifestations of a familial lymphoproliferative disorder. ⁶² ⁵⁷	Fraumeni JF...Leventhal BG	806230	1975
28	Familial Hodgkin's disease: an environmental and genetic disorder. ⁶² ⁵⁷	Vianna NJ...Wolfgang P	4137662	1974
29	Family studies in Hodgkin's disease. ⁶² ⁵⁷	Fraumeni JF	4842358	1974
30	Familial Hodgkin's disease. ⁶² ⁵⁷	Creagan ET...Fraumeni JF	4115609	1972
31	Mortality from Hodgkin's disease in the United States. Evidence for the multiple-aetiology hypothesis. ⁶² ⁵⁷	Cole P...Aisenberg A	4177934	1968
32	Epidemiology of Hodgkin's disease. ⁶² ⁵⁷	MacMahon B	5329907	1966
33	[FAMILIAL HODGKIN'S DISEASE]. ⁶² ⁵⁷	MANIGAND G...DEPARIS M	14154061	1964
34	Subtype distribution of lymphomas in northwestern Iran: a retrospective analysis of 659 cases according to World Health Organization classification. ⁶² ⁴¹	Jalili J...Hajihoseinlou F	36224530	2022
35	Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta analysis. ⁶² ⁴¹	Fagundes RBC...Medeiros KS	36181035	2022
36	Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma. ⁶² ⁴¹	Bellitti E...Ingravallo G	36135049	2022
37	Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. ⁶² ⁴⁶	Van Vlierberghe P...Speleman F	19775296	2009
38	Infection and lymphoma. ⁵⁷	Ambinder R	14523136	2003
39	The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. ⁵³ ⁶²	Aldinucci D...Carbone A	20527019	2010
40	Common misdiagnoses in lymphomas and avoidance strategies. ⁵³ ⁶²	Chan JK...Kwong YL	20227918	2010
41	B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. ⁵³ ⁶²	Carbone A...Cabras A	20398809	2010
42	The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. ⁵³ ⁶²	Koreishi AF...Teruya-Feldstein J	20065852	2010
43	PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. ⁵³ ⁶²	Feldman AL...Macon WR	20118907	2010
44	IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. ⁵³ ⁶²	Broderick P...Houlston R	19804451	2010
45	Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236. ⁵³ ⁶²	Andersson E...Claesson HE	19931589	2010
46	Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas. ⁵³ ⁶²	Birgersdotter A...Ernberg I	20093237	2010
47	Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond. ⁵³ ⁶²	Aldinucci D...Carbone A	20093413	2010
48	IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. ⁵³ ⁶²	Aldinucci D...Carbone A	19821826	2010
49	Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma. ⁵³ ⁶²	Bhargava P...Kadin ME	19550297	2010
50	TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. ⁵³ ⁶²	Vahdat AM...Hansen HP	19890373	2010

Sources

Genes for Lymphoma, Hodgkin, Classic

Genes related to Lymphoma, Hodgkin, Classic (2 elite genes):

(show top 50) (show all 85)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	KLHDC8B	Kelch Domain Containing 8B	Protein Coding	1063.9	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ DISEASES inferred ¹⁴ GeneCards inferred via : Disorders (show sections)	19706467
2	TP53	Tumor Protein P53	Protein Coding	407.48	Pathogenic ⁵ DISEASES inferred ¹⁴
3	PVT1	Pvt1 Oncogene	RNA Gene	154.45	Experimental evidence ³⁷ DISEASES inferred ¹⁴	21037568
4	MIR155	MicroRNA 155	RNA Gene	60.55	Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	16041695
5	MIR21	MicroRNA 21	RNA Gene	55.69	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
6	MIR20A	MicroRNA 20a	RNA Gene	55.04	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
7	MIR18A	MicroRNA 18a	RNA Gene	54.86	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
8	MIR200A	MicroRNA 200a	RNA Gene	54.22	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
9	MIR30A	MicroRNA 30a	RNA Gene	53.87	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
10	MIR30B	MicroRNA 30b	RNA Gene	53.83	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
11	MIR140	MicroRNA 140	RNA Gene	53.63	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
12	MIR186	MicroRNA 186	RNA Gene	53.48	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
13	MIR614	MicroRNA 614	RNA Gene	53.29	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
14	MIR520A	MicroRNA 520a	RNA Gene	53.08	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
15	MIR374A	MicroRNA 374a	RNA Gene	52.95	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19775296
16	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	20.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11004694 12754742 12875982 (more) 9209650 9777980 17965727 9531614 2164839 15251128 16140928 8389737 8055109 7982672 1850308 7528856 7591296 9032281 9935206 8833395 1333270 1349939 2280610 19760074 17106517 16200333 12568298 10950145 19760381 17389336 15093542 11418184 10881697 9645450 1849627 2152774 19823169 7745117 15322151 11729213 10908157 10727988 8187071 19890373 15034047 11971184 8581383 8218985 8391931 15356338 11838744 11552987 8896393 19540595 16152613 16506595 15131062 8396378 16244703 15058220 11494447 9058726 8568238 7856755 8103064 20302775 8744679 9208978
17	IRF4	Interferon Regulatory Factor 4	Protein Coding	17	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	18410414 19821826 19804451 (more) 10706878
18	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	16.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	20227918 11697652 9638979 (more) 9490693 12500399 8781433 17325487 11263444 7655001 9250148
19	PAX5	Paired Box 5	Protein Coding	16.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12609061 16648862 20118907 (more) 12360049 9694719 16185503 20398809 15041542 19465900 14690578 17535098
20	CSF3	Colony Stimulating Factor 3	Protein Coding	16.41	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11378548 10067091 17459049 (more) 7534963 17994119 10613458 9053502 9292744 8590858 1693295 8733686 9674019 16182183 7543069 9130625 7506247 17324009 10197794 10048953 10791904 1581417 18940680 11019835 12200356 11486403 9818688 9088081 8636780 8542941 19275275 16777623 16371028 19307667 18766966 14512943 11035615 9827930 1283546 1450074 12721249 10350339 9658727 7692199 12028037 10093688 9095335 7540401 10516673 16400345
21	BCL6	BCL6 Transcription Repressor	Protein Coding	16.39	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15339680 8555467 11290603 (more) 7472775 12393409 8638618 11157493 15998973 10569135 9209651 9746758 8623923 15256116
22	TNFSF8	TNF Superfamily Member 8	Protein Coding	15.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9209650 7528856 8701986 (more) 10908157 10512160 9058727
23	BCL2	BCL2 Apoptosis Regulator	Protein Coding	14.67	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12651235 1433367 8322700 (more) 8388163 11119123 7665145 9717525 1427749 8057670 2185367 8729046 1916688 16109607 17006259 7534007 18758641 7524301 8774139 17673811 12433696 1333273 9349231 7474920 1868240 1899539 9021697 20090100 18024321 17510532 1750500 19557638 9276187 8209865 8148417 1656757 15809450 9310494 8630413 7914127 1632463 2185366 15846077 9578089 7790991 9542744 11839668 1817429 7761357 1321789 15635876 8080035
24	PTPRC	Protein Tyrosine Phosphatase Receptor Type C	Protein Coding	14.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1376944 8322699 1359849
25	TIA1	TIA1 Cytotoxic Granule Associated RNA Binding Protein	Protein Coding	13.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9176382 20065852
26	TRAF1	TNF Receptor Associated Factor 1	Protein Coding	13.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15644776 20302775 19540595 (more) 11144929 19698991 12754742
27	GZMB	Granzyme B	Protein Coding	13.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11756176 10091777 14712286
28	IL2	Interleukin 2	Protein Coding	13.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1756538 8204352 2043594 (more) 12185517 1878686 7493395 8832017 14654080 1868045 2380992 7833103 9515791 9407718 8907277 8535662 8002002 1283546 1450074 1933892 9130625 15194535 7893977 1691591 15688386 8506943 2102116 11355944 2036661 10609806 8625370 10689713
29	CCL17	C-C Motif Chemokine Ligand 17	Protein Coding	12.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15994922 19591376 11420464 (more) 18541724 12181269
30	IL3	Interleukin 3	Protein Coding	12.76	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1693295 1951632 7873999 (more) 15621820 12485944 1581417 8492461 9130625 1450074 1283546 9292744 8639889 7689778 8542941
31	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	12.27	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8394483 8915517 1333270 (more) 8506943 7710984 9528846 11781710 8508408 9166099 9437500 8494993 11494447 2049320 7719243 8535662 8019399 8260527 8067207 1730512 12764738 8512810 7679589 2280610 1917143
32	CSF2	Colony Stimulating Factor 2	Protein Coding	12.2	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1728202 7703829 8534765 (more) 1951632 8492461 11398878
33	POU2AF1	POU Class 2 Homeobox Associating Factor 1	Protein Coding	12.15	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17562619 11280769 15796964
34	MS4A1	Membrane Spanning 4-Domains A1	Protein Coding	11.99	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9777980 12360049 14632776
35	JAK2	Janus Kinase 2	Protein Coding	11.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17652621 19704259 19666866 (more) 12478664 17460466 9926251
36	IL9	Interleukin 9	Protein Coding	11.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1908723 1283279 9505195 (more) 7858153 9454968 16519698 14562126
37	CD68	CD68 Molecule	Protein Coding	11.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1320954
38	CD40	CD40 Molecule	Protein Coding	11.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7507299 7530508 8604696 (more) 9935206 15131062 7522624 8916443 10505772
39	CFLAR	CASP8 And FADD Like Apoptosis Regulator	Protein Coding	11.46	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15354734 16441226 17659339 (more) 18042067 17932249 11943736 15096587 15878978 16761935
40	REL	REL Proto-Oncogene, NF-KB Subunit	Protein Coding	11.18	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15644776 14755244 18245482 (more) 15870177 11830502
41	STAT6	Signal Transducer And Activator Of Transcription 6	Protein Coding	11.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17652621 19440213 15044251
42	TRAF3	TNF Receptor Associated Factor 3	Protein Coding	11.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8892903 19540595 19954665 (more) 11023520
43	IL13	Interleukin 13	Protein Coding	11	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11585386 19417211 12685255 (more) 15163701 9130625 12152987 15044251 15194535 11133768 11697338 10529786 11815733 19931589 11318902
44	SH2D1A	SH2 Domain Containing 1A	Protein Coding	10.72	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12224001 12594824 15315965
45	SPI1	Spi-1 Proto-Oncogene	Protein Coding	10.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15339679 11696441 16648862 (more) 15796964
46	RYBP	RING1 And YY1 Binding Protein	Protein Coding	10.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15470680 16528373
47	BCL2L1	BCL2 Like 1	Protein Coding	10.66	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9021697 8630413 8616083 (more) 8686741
48	CHRDL1	Chordin Like 1	Protein Coding	10.6	Novoseek inferred ⁵³	17539776 15732141 19075188 (more) 12939740 16007868 17938252 20093237 12933571 18704935 12152987 19666866 20527019 16284059 16614247 17876757 19607667
49	TNFRSF1A	TNF Receptor Superfamily Member 1A	Protein Coding	10.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9649158 20302775 14764685 (more) 16198418 15322151 17647199 12389614 11418184
50	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	10.5	DISEASES inferred ¹⁴ ¹⁴

Sources

Variations for Lymphoma, Hodgkin, Classic

ClinVar genetic disease variations for Lymphoma, Hodgkin, Classic:

IMPROVED

⁵

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.1118del (p.Lys373fs)	DEL	Pathogenic	1052297		GRCh37: 17:7572991-7572991 GRCh38: 17:7669673-7669673
2	KLHDC8B	NM_173546.3(KLHDC8B):c.-158C>T	SNV	Pathogenic	273	rs387906223	GRCh37: 3:49209095-49209095 GRCh38: 3:49171662-49171662
3	MYC	NM_002467.6(MYC):c.77A>G (p.Asn26Ser)	SNV	Uncertain Significance	1679939		GRCh37: 8:128750540-128750540 GRCh38: 8:127738294-127738294
4	MET	NM_000245.4(MET):c.2975C>T (p.Thr992Ile)	SNV	Uncertain Significance	41624	rs56391007	GRCh37: 7:116411990-116411990 GRCh38: 7:116771936-116771936
5	KRAS	NM_004985.5(KRAS):c.436G>A (p.Ala146Thr)	SNV	Uncertain Significance	197243	rs121913527	GRCh37: 12:25378562-25378562 GRCh38: 12:25225628-25225628
6	FGFR3	NM_000142.5(FGFR3):c.1181C>T (p.Thr394Met)	SNV	Uncertain Significance	576979	rs747694886	GRCh37: 4:1806162-1806162 GRCh38: 4:1804435-1804435
7	FGFR4	NM_213647.3(FGFR4):c.407C>T (p.Pro136Leu)	SNV	Likely Benign	1679938		GRCh37: 5:176517797-176517797 GRCh38: 5:177090796-177090796

Copy number variations for Lymphoma, Hodgkin, Classic from CNVD:

⁶ (show top 50) (show all 204)

#	CNVD ID	Chromosome	Start	End	Type	CNVD Disease
1	15434	1	115570986	115748025	Copy number	Hodgkin''s lymphoma
2	18148	1	144224941	245407169	Copy number	Hodgkin''s lymphoma
3	21362	1	158258490	227249364	Copy number	Hodgkin''s lymphoma
4	29781	1	235850830	237390561	Copy number	Hodgkin''s lymphoma
5	29922	1	238038528	245407169	Copy number	Hodgkin''s lymphoma
6	35390	1	6293700	18251002	Copy number	Hodgkin''s lymphoma
7	37216	1	87388008	120033702	Copy number	Hodgkin''s lymphoma
8	37460	1	9146813	16679690	Copy number	Hodgkin''s lymphoma
9	38491	10	102895110	124244273	Copy number	Hodgkin''s lymphoma
10	40197	10	125057756	126954997	Copy number	Hodgkin''s lymphoma
11	40637	10	131215760	132635356	Copy number	Hodgkin''s lymphoma
12	41620	10	214400	133778456	Copy number	Hodgkin''s lymphoma
13	41883	10	25240974	36004765	Copy number	Hodgkin''s lymphoma
14	43571	10	46999355	135111152	Copy number	Hodgkin''s lymphoma
15	43572	10	46999355	48101366	Copy number	Hodgkin''s lymphoma
16	43573	10	46999355	49467140	Copy number	Hodgkin''s lymphoma
17	44594	10	60095355	78914295	Copy number	Hodgkin''s lymphoma
18	44784	10	6277674	8346525	Copy number	Hodgkin''s lymphoma
19	45116	10	67551761	78914295	Copy number	Hodgkin''s lymphoma
20	46267	10	79687952	85721525	Copy number	Hodgkin''s lymphoma
21	46788	10	86278375	101096913	Copy number	Hodgkin''s lymphoma
22	49260	11	104569097	133732868	Copy number	Hodgkin''s lymphoma
23	50177	11	115327798	134437143	Copy number	Hodgkin''s lymphoma
24	52493	11	178227	35140556	Copy number	Hodgkin''s lymphoma
25	57515	11	63560139	72573784	Copy number	Hodgkin''s lymphoma
26	57783	11	64800000	75000000	Gain	Hodgkin''s lymphoma
27	58506	11	68129639	134437143	Copy number	Hodgkin''s lymphoma
28	60254	11	84447402	105734987	Copy number	Hodgkin''s lymphoma
29	60677	11	89286313	104569095	Copy number	Hodgkin''s lymphoma
30	64335	12	126737931	132373208	Copy number	Hodgkin''s lymphoma
31	65226	12	152534	16164790	Copy number	Hodgkin''s lymphoma
32	65227	12	152534	525774777	Copy number	Hodgkin''s lymphoma
33	67817	12	4490384	44739500	Copy number	Hodgkin''s lymphoma
34	67821	12	45000000	56400000	Gain	Hodgkin''s lymphoma
35	68783	12	51500000	63100000	Gain	Hodgkin''s lymphoma
36	68979	12	52417126	60370345	Copy number	Hodgkin''s lymphoma
37	69531	12	55627899	56288135	Copy number	Hodgkin''s lymphoma
38	70095	12	58245748	132373208	Copy number	Hodgkin''s lymphoma
39	70715	12	64263728	66931770	Copy number	Hodgkin''s lymphoma
40	71442	12	70000000	82000000	Gain	Hodgkin''s lymphoma
41	72563	12	82669309	120958351	Copy number	Hodgkin''s lymphoma
42	75245	13	18397782	106691271	Copy number	Hodgkin''s lymphoma
43	75246	13	18397782	114117460	Copy number	Hodgkin''s lymphoma
44	75871	13	25400000	38500000	Loss	Hodgkin''s lymphoma
45	75878	13	25500000	32200000	Loss	Hodgkin''s lymphoma
46	79388	13	71000000	83000000	Loss	Hodgkin''s lymphoma
47	83222	14	19570807	42171562	Copy number	Hodgkin''s lymphoma
48	83386	14	20383489	53262838	Copy number	Hodgkin''s lymphoma
49	83387	14	20383489	56623380	Copy number	Hodgkin''s lymphoma
50	85558	14	48879628	106278173	Copy number	Hodgkin''s lymphoma

Sources

Expression for Lymphoma, Hodgkin, Classic

Search GEO for disease gene expression data for Lymphoma, Hodgkin, Classic.

Sources

Pathways for Lymphoma, Hodgkin, Classic

Pathways related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	miRNAs involved in DNA damage response ⁷⁴	10.75	TP53 MIR21 MIR20A MIR18A
2	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma ⁷⁴	10.21	MIR21 MIR200A

Sources

GO Terms for Lymphoma, Hodgkin, Classic

Cellular components related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.58	MIR30B MIR30A MIR21 MIR20A MIR200A MIR18A
2	extracellular vesicle	GO:1903561	9.26	MIR30B MIR30A MIR21 MIR20A

Biological processes related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cellular response to lipopolysaccharide	GO:0071222	9.72	MIR21 MIR20A MIR140 CSF3
2	miRNA-mediated gene silencing	GO:0035195	9.64	MIR520A MIR374A MIR30B MIR30A MIR21 MIR20A
3	negative regulation of gene expression	GO:0010629	9.43	TP53 MIR21 MIR20A MIR186 MIR155 MIR140
4	negative regulation of regulatory T cell differentiation	GO:0045590	9.26	MIR30B MIR21
5	positive regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching	GO:1905932	9.16	MIR18A MIR140

Molecular functions related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.61	TP53 MIR374A MIR30A MIR21 MIR20A MIR186
2	mRNA base-pairing translational repressor activity	GO:1903231	9.36	MIR520A MIR374A MIR30B MIR30A MIR21 MIR20A